低级别异型增生低覆盖全基因组测序可强预测溃疡性结肠炎进展期肿瘤风险
本研究为回顾性多中心验证的病例对照研究,纳入122例溃疡性结肠炎患者的270份低级别异型增生样本,比较进展组40例与未进展组82例。结果显示低级别异型增生病变的体细胞拷贝数改变负荷在进展组显著高于未进展组(发现队列p=2×10⁻⁶),单变量分析OR=36(p=9×10⁻⁷),优于病变大小、形状和局灶性等临床危险因素。拷贝数改变负荷联合不完全低级别异型增生切除的多变量模型预测效果最佳,病变内遗传异质性未干扰预测。
要点
- 低级别异型增生病变的拷贝数改变负荷可预测溃疡性结肠炎患者未来进展期肿瘤风险。
- 进展组拷贝数改变负荷显著高于未进展组,OR=36(p=9×10⁻⁷)。
- 拷贝数改变负荷联合不完全低级别异型增生切除的多变量模型预测效果最佳。
核心结论
- 测量低级别异型增生病变中的拷贝数改变可准确预测炎症性肠病患者的进展期肿瘤风险,并可能支持临床管理。
研究设计与样本
- 回顾性多中心验证的病例对照研究,使用122例溃疡性结肠炎患者的270份低级别异型增生样本。
- 进展组40例为低级别异型增生诊断后约5年内诊断为进展期肿瘤者,未进展组82例为随访期间未发生进展期肿瘤者。
- 从基线低级别异型增生病变提取DNA,进行低覆盖全基因组测序并处理数据以检测拷贝数改变。
- 采用生存分析评估拷贝数改变作为未来进展期肿瘤风险预测因子。
主要发现
- 进展组拷贝数改变负荷显著高于未进展组(发现队列p=2×10⁻⁶)。
- 单变量分析中拷贝数改变负荷是进展期肿瘤风险的非常显著预测因子(OR=36;p=9×10⁻⁷),优于病变大小、形状和局灶性等现有临床危险因素。
- 拷贝数改变负荷联合已知临床危险因素不完全低级别异型增生切除的多变量模型达到最佳风险预测。
- 低级别异型增生病变内遗传异质性未干扰风险预测。
临床怎么用
- 作者认为低级别异型增生病变中拷贝数改变的测量可准确预测炎症性肠病的进展期肿瘤风险,并可能支持临床管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of developing advanced neoplasia (AN; colorectal cancer and/or high-grade dysplasia) in ulcerative colitis (UC) patients with a low-grade dysplasia (LGD) lesion is variable and difficult to predict. This is a major challenge for effective clinical management. OBJECTIVE: We aimed to provide accurate AN risk stratification in UC patients with LGD. We hypothesised that the pattern and burden of somatic genomic copy number alterations (CNAs) in LGD lesions could predict future AN risk. DESIGN: We performed a retrospective multicentre validated case-control study using n=270 LGD samples from n=122 patients with UC. Patients were designated progressors (n=40) if they had a diagnosis of AN in the ~5 years following LGD diagnosis or non-progressors (n=82) if they remained AN-free during follow-up. DNA was extracted from the baseline LGD lesion, low-coverage whole genome sequencing performed and data processed to detect CNAs. Survival analysis was used to evaluate CNAs as predictors of future AN risk. RESULTS: CNA burden was significantly higher in progressors than non-progressors (p=2×10-6 in discovery cohort) and was a very significant predictor of AN risk in univariate analysis (OR=36; p=9×10-7), outperforming existing clinical risk factors such as lesion size, shape and focality. Optimal risk prediction was achieved with a multivariate model combining CNA burden with the known clinical risk factor of incomplete LGD resection. Within-LGD lesion genetic heterogeneity did not confound risk prediction. CONCLUSION: Measurement of CNAs in LGD is an accurate predictor of AN risk in inflammatory bowel disease and is likely to support clinical management.
引用
- Al Bakir I, Curtius K, Cresswell GD, et al. Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis. Gut. 2025. PMID: 39880602. doi:10.1136/gutjnl-2024-333353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。